ReviewExtracellular vesicles and circulating nucleic acids2022
Nucleic acid functionalized extracellular vesicles as promising therapeutic systems for nanomedicine.
Review in Extracellular vesicles and circulating nucleic acids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Engineering spherical nucleic acids for precision cancer therapy: design strategies and medical applications.Theranostics · 2026Review
- 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026Review
- Endothelial cell-targeting aptamer-empowered exosomes accelerate wound healing by promoting specialized angiogenesis in type 1 diabetic mice.Stem cell research & therapy · 2025Article
- Magnetic engineered bone mesenchymal stem cells-derived exosomes for targeted acute lung injury therapy.Stem cell research & therapy · 2025Article
- Exosomes in ovarian cancer: Impact on drug resistance and advances in SERS detection techniques.Journal of pharmaceutical analysis · 2025Review
- Extracellular vesicles in burn injury: roles, mechanisms, and applications.Burns & trauma · 2025Review
- Hydrogel-based biomaterials for brain regeneration after stroke: Gap to clinical translation.Biomaterials translational · 2025Review
- Engineered extracellular vesicles for tissue repair and regeneration.Burns & trauma · 2024Review
- Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy.Theranostics · 2024Article
- CRISPR-Cas9 delivery strategies with engineered extracellular vesicles.Molecular therapy. Nucleic acids · 2023Review
- Plant-Derived Extracellular Vesicles and Their Exciting Potential as the Future of Next-Generation Drug Delivery.Biomolecules · 2023Review
- Engineered EVs designed to target diseases of the CNS.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- New insights of engineered extracellular vesicles as promising therapeutic systems.Extracellular vesicles and circulating nucleic acids · 2023Article
- Carboxypeptidase E and its splice variants: Key regulators of growth and metastasis in multiple cancer types.Cancer letters · 2022Review
- Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges.Pharmaceutics · 2022Review
- Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections.Clinical and translational medicine · 2022Review
- Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment.Pharmaceutics · 2022Review
- Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy.Theranostics · 2022Review
- Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer EffectFrontiers in medicine · 2022Article
- Engineered mammalian and bacterial extracellular vesicles as promising nanocarriers for targeted therapy.Extracellular vesicles and circulating nucleic acids · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs), as natural carriers, are regarded as a new star in nanomedicine due to their excellent biocompatibility, fascinating physicochemical properties, and unique biological regulatory functions. However, there are still some challenges to using natural EVs, including poor targeting ability and the clearance from circulation, which may limit their further development and clinical use. Nucleic acid has the functions of programmability, targeting, gene therapy, and immune regulation. Owing to the engineering design and modification by integrating functional nucleic acid, EVs offer excellent performances as a therapeutic system
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.